{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:36Z","timestamp":1790697936476,"version":"4.1.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To examine the long-term visual and morphologic outcomes in a large series of patients with pachychoroid neovasculopathy treated with intravitreal antivascular endothelial growth factor (anti-VEGF) injections.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A retrospective, observational study of anti-VEGF injections was performed in 249 eyes of 237 patients with pachychoroid neovasculopathy at 1 retina center over 7 years.\n                    <jats:bold>Results:<\/jats:bold>\n                    Mean patient age was 65.5 years and mean follow-up was 1.91 years (range, 3 months to 7.14 years). At baseline, mean best-corrected visual acuity (BCVA) was 20\/60 Snellen, with an improvement of 2.30 Early Treatment Diabetic Retinopathy Study (ETDRS) letters by the study endpoint (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u2009.04). From baseline to endpoint, mean central subfield thickness decreased by 78.2 \u03bcm, and mean choroidal thickness decreased by 35.4 \u03bcm (each\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009&lt;\u2009.05). Treat-and-extend was utilized in 192 eyes (77.9%), with a 42.3% recurrence rate on extension. Treatment cessation was trialed in 70 eyes (28.1%), of which 53 eyes required no further treatment. Adjunct photodynamic therapy was utilized in 34 eyes (13.7%), resulting in a mean vision improvement of 0.44 ETDRS letters, compared with a mean improvement of 2.30 ETDRS letters in patients who received anti-VEGF only (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u2009.6).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Anti-VEGF therapy improved BCVA and anatomic features in this large cohort of patients with pachychoroid neovasculopathy. Continued treatment was required in 196 eyes (78.7%) at the study endpoint.\n                  <\/jats:p>","DOI":"10.1177\/24741264251381985","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:57:46Z","timestamp":1761908266000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics and Outcomes of Antivascular Endothelial Growth Factor Therapy in a Large Cohort of Patients With Pachychoroid Neovasculopathy"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3168-8933","authenticated-orcid":false,"given":"Carolin","family":"Aizouki","sequence":"first","affiliation":[{"name":"University of Alberta, Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7586-0154","authenticated-orcid":false,"given":"Amit V.","family":"Mishra","sequence":"additional","affiliation":[{"name":"Alberta Retina Consultants, Edmonton, Alberta, Canada"},{"name":"University of Alberta, Department of Ophthalmology and Visual Sciences, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8281-8954","authenticated-orcid":false,"given":"Graeme K.","family":"Loh","sequence":"additional","affiliation":[{"name":"Alberta Retina Consultants, Edmonton, Alberta, Canada"},{"name":"University of Alberta, Department of Ophthalmology and Visual Sciences, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishanthan","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Alberta Retina Consultants, Edmonton, Alberta, Canada"},{"name":"University of Alberta, Department of Ophthalmology and Visual Sciences, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.J.","family":"Greve","sequence":"additional","affiliation":[{"name":"Alberta Retina Consultants, Edmonton, Alberta, Canada"},{"name":"University of Alberta, Department of Ophthalmology and Visual Sciences, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ehmann","sequence":"additional","affiliation":[{"name":"Alberta Retina Consultants, Edmonton, Alberta, Canada"},{"name":"University of Alberta, Department of Ophthalmology and Visual Sciences, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parampal S.","family":"Grewal","sequence":"additional","affiliation":[{"name":"Alberta Retina Consultants, Edmonton, Alberta, Canada"},{"name":"University of Alberta, Department of Ophthalmology and Visual Sciences, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Seamone","sequence":"additional","affiliation":[{"name":"Alberta Retina Consultants, Edmonton, Alberta, Canada"},{"name":"University of Alberta, Department of Ophthalmology and Visual Sciences, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v18i2.13188"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0158-4"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14683"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S285257"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211036290"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep16204"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28484-w"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2023.2194983"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Lai TYY Staurenghi G Lanzetta P et al Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause twelve-month results of the MINERVA study. Retina. 2018;38:1464-1477.","DOI":"10.1097\/IAE.0000000000001744"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22144"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212055"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-018-0562-0"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91589-2"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0107"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38504-y"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-021-01754-9"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2022.2068150"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-021-02022-1"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01418-z"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.6.709"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Lee JH Lee KI. One-year results of adjunctive photodynamic therapy for type 1 neovascularization associated with thickened choroid. Retina. 2016;36(5):889-895.","DOI":"10.1097\/IAE.0000000000000809"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S334641"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251381985","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251381985","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251381985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:24:22Z","timestamp":1790695462000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251381985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/24741264251381985"],"URL":"https:\/\/doi.org\/10.1177\/24741264251381985","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}